Natalizumab observational programme: assessment of long-term safety and impact on disease activity and progression of natalizumab in patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Wiendl, H.
Butzkueven, H.
Trojano, M.
Goodin, D.
Kappos, L.
Desgrandchamps, D.
机构：
[1] Univ Wurzburg, Wurzburg, Germany
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
[3] Univ Bari, Bari, Italy
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Univ Basel Hosp, CH-4031 Basel, Switzerland
[6] Biogen Idec Int GmbH, Zug, Switzerland
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 50 条
  • [31] Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
    Alroughani, R.
    Al Hashel, J.
    Thussu, A.
    Ahmed, S. F.
    MEDICAL PRINCIPLES AND PRACTICE, 2013, 22 (05) : 495 - 499
  • [32] Long-term assessment of No Evidence of Disease Activity (NEDA) in patients with relapsing-remitting multiple sclerosis
    De Stefano, N.
    Stromillo, M. L.
    Giorgio, A.
    Bartolozzi, M. L.
    Battaglini, M.
    Baldini, M.
    Portaccio, E.
    Amato, M. P.
    Sormani, M. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 26 - 26
  • [33] Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet"
    Popova, E. V.
    Brylev, L. V.
    Davydovskaya, M. V.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 79 - +
  • [34] Efficacy and safety of natalizumab in children with highly active relapsing-remitting multiple sclerosis
    Karageorgiou, Klimentini E.
    Polyzoi, Maria
    Tzitzika, Moira
    Xatzi, Ioanna
    Alexoudi, Athanasia
    MULTIPLE SCLEROSIS, 2008, 14 : S51 - S51
  • [35] Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis
    Melin, A.
    Outteryck, O.
    Collongues, N.
    Zephir, H.
    Fleury, M. C.
    Blanc, F.
    Lacour, A.
    Ongagna, J. C.
    Berteloot, A. S.
    Vermersch, P.
    de Seze, J.
    JOURNAL OF NEUROLOGY, 2012, 259 (06) : 1215 - 1221
  • [36] Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis
    A. Melin
    O. Outteryck
    N. Collongues
    H. Zéphir
    M. C. Fleury
    F. Blanc
    A. Lacour
    J. C. Ongagna
    A. S. Berteloot
    P. Vermersch
    J. de Sèze
    Journal of Neurology, 2012, 259 : 1215 - 1221
  • [37] Residual adaptive inflammation in the cerebrospinal fluid after long-term natalizumab treatment in patients with relapsing-remitting multiple sclerosis
    Buhelt, Sophie
    Hansen, Malene Bredahl
    Soendergaard, Helle Bach
    El Mahdaoui, Sahla
    Hansen, Marie Mathilde
    Mahler, Mie Reith
    Christensen, Jeppe Romme
    Sellebjerg, Finn
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 580 - 580
  • [38] Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis
    Prosperini, L.
    Mancinelli, C. R.
    Gianni, C.
    Barletta, V.
    Fubelli, F.
    Borriello, G.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 469 - 470
  • [39] Natalizumab: A guide to its use in relapsing-remitting multiple sclerosis
    Keating G.M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2014, 30 (2) : 48 - 54
  • [40] Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter
    Pato Pato, A.
    Costa Arpin, E.
    Rodriguez Regal, A.
    Rodriguez Constenla, I
    Cimas Hernando, I
    Munoz Pousa, I
    Naya Rios, L.
    Lorenzo Gonzalez, J. R.
    Amigo Jorrin, M. C.
    Prieto Gonzalez, J. M.
    NEUROLOGIA, 2021, 36 (05): : 346 - 352
12345